AU Patent

AU2016296878B2 — Chiral diaryl macrocycles and uses thereof

Assigned to Turning Point Therapeutics Inc · Expires 2020-12-17 · 5y expired

What this patent protects

This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7

USPTO Abstract

This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7

Drugs covered by this patent

Augtyro (REPOTRECTINIB) · Bristol

Patent Metadata

Patent number: AU2016296878B2
Jurisdiction: AU
Classification: —
Expires: 2020-12-17
Drug substance claim: No
Drug product claim: No
Assignee: Turning Point Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.